Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
RA’ANANA, Israel and NEW YORK, May 30, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 1:30 p.m. EDT. The conference will be held in New York, NY.
A live audio webcast of the presentation will be available by visiting the Investors section of the UroGen Pharma website at http://investors.urogen.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.
About UroGen Pharma Ltd.
UroGen Pharma (NASDAQ:URGN) is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACTS: UroGen Pharma Ltd. Gary Titus Chief Financial Officer [email protected] 646-768-9531 Or Burns McClellan, Inc. Steve Klass [email protected] 212-213-0006
